First clinical experience of isatuximab safety and tolerability in relapsed and refractory multiple myeloma: real-world data from a compassionate use program in Germany.

MLA

Leitner, Theo, et al. “First Clinical Experience of Isatuximab Safety and Tolerability in Relapsed and Refractory Multiple Myeloma: Real-World Data from a Compassionate Use Program in Germany.” Frontiers in Hematology, June 2024, pp. 1–7. EBSCOhost, https://doi.org/10.3389/frhem.2024.1335161.

APA

Leitner, T., Khandanpour, C., Wendelin, K., Oduncu, F., Kimmich, C., Naumann, R., Kull, M., Goldschmidt, H., Ehmer, M., Kiewitz, C., & Salwender, H. (2024). First clinical experience of isatuximab safety and tolerability in relapsed and refractory multiple myeloma: real-world data from a compassionate use program in Germany. Frontiers in Hematology, 1–7. https://doi.org/10.3389/frhem.2024.1335161

Chicago

Leitner, Theo, Cyrus Khandanpour, Knut Wendelin, Fuat Oduncu, Christoph Kimmich, Ralph Naumann, Miriam Kull, et al. 2024. “First Clinical Experience of Isatuximab Safety and Tolerability in Relapsed and Refractory Multiple Myeloma: Real-World Data from a Compassionate Use Program in Germany.” Frontiers in Hematology, June, 1–7. doi:10.3389/frhem.2024.1335161.